Drug Discovery
Expand Your Drug Discovery Pipeline with Live Cell Analysis
As the cost of bringing new drugs to market continues to grow, so do the pressures around increasing efficiency and productivity throughout the discovery and development cycle. And, no matter the stage, cell-based analysis plays a critical role in discovery, screening and toxicity studies.
Agilent Cell Analysis technology provides unique capabilities for drug discovery and toxicity studies:
- De-risk your drug discovery pipeline, identify cardiotoxic effects and assess cardiac disease models in real time using the xCELLigence RTCA Cardio/CardioECR/ePacer systems.
- Perform real-time, high throughput monitoring of compound-mediated cytotoxic responses with xCELLigence RTCA instruments.
- Compatible with a variety of high throughput automated platforms, NovoCyte flow cytometers enable the analysis of specific cell type responses such as receptor expression, cytokine detection, and proliferation, to small molecules or antibody-drug conjugates.
Search scientific publications that reference and/or cite Agilent Cell Analysis products.
For Research Use Only. Not for use in diagnostic procedures.
Application Details
Application Notes
Cardiotoxicity Assessment of Antiviral Drugs Using the Agilent xCELLigence RTCA CardioECR System
- PDF/ Found In: Application Notes
- Date : 21 May 2024
- File Size : 1.55 MB
Assessing the Impact of Drug Treatment on Cardiomyocyte Function
- PDF/ Found In: Application Notes
- Date : 12 Mar 2021
- File Size : 1.01 MB
Metabolic Profiling of Cells in 3D Cultures using MitoXpress Xtra and pH-Xtra Assays
- PDF/ Found In: Application Notes
- Date : 14 Aug 2020
- File Size : 875.55 KB
Literature
- Application Notes
-
Cardiotoxicity Assessment of Antiviral Drugs Using the Agilent xCELLigence RTCA CardioECR System
This study used the Agilent xCELLigence RTCA CardioECR system with human iPSC-derived cardiomyocytes (hiPSC-CMs) to evaluate cardiac safety/toxicity of antiviral drugs.- Application Notes
- English
- 21 May 2024
- 1.55 MB
Assessing the Impact of Drug Treatment on Cardiomyocyte Function
A demonstration of combining microelectrode-based iPS cardiomyocyte contractility measurements with microplate-based bioenergetics assessment to characterize cellular responses to drug treatment.- Application Notes
- English
- 12 Mar 2021
- 1.01 MB
Metabolic Profiling of Cells in 3D Cultures using MitoXpress Xtra and pH-Xtra Assays
Two workflows using MitoXpress Xtra and pH-Xtra probes to investigate cell metabolism in intact RAFT 3D collagen structures on fluorescent plate readers.- Application Notes
- English
- 14 Aug 2020
- 875.55 KB
Analysis of Phosphorylated STAT Protein Signaling in Lymphocytes Using Flow Cytometry
Examines the phosphorylation of signal transducer and activator of transcription (STAT) proteins in response to cytokine stimulation using a phosphoflow technique.- Application Notes
- English
- 02 Jul 2020
- 1.13 MB
Cell-Based Screening for Drug-Induced Mitochondrial Toxicity
A demonstration of the performance of the Agilent MitoXpress Xtra oxygen consumption assay for identifying drug induced mitocondrial toxicity.- Application Notes
- English
- 08 Jan 2020
- 871.66 KB
Targeting Energy Metabolism for Cancer Therapeutic Discovery using Agilent Seahorse XF Technology
Measuring bioenergetic phenotype, cellular ATP production rates, and mitochondrial and glycolytic function with Agilent Seahorse XF technology can reveal metabolic vulnerabilities in cancer cells to advance cancer therapeutics.- Application Notes
- English
- 12 Jun 2019
- 503.32 KB
Direct Measurements of Cellular Metabolism for Identification of Mitochondrial Drug Targets
An overview of how the Agilent Seahorse XF Cell Mito Stress Test and XF PMP workflows can be applied to mitochondrial and metabolic target identification studies.- Application Notes
- English
- 10 Jun 2019
- 389.41 KB
Measuring Microbial Metabolism
Correlating Microbial Proliferation with Antibiotic Resistance using the MitoXpress Xtra Oxygen Consumption Assay- Application Notes
- English
- 25 Feb 2019
- 489.30 KB
Agilent LC/MSD XT Single Quadrupole Open Access System for Synthetic Chemists
Using the Agilent LC/MSD XT in open access mode provides tremendous user flexibility to automate compound confirmation and purity/impurity analysis- Application Notes
- English
- 14 Jun 2017
- 2.08 MB
Spectrophotometric Monitoring of the Photoreactivity of Fluphenazine and its Use as a Photoaffinity Label for Trypanothione Reductase
Demonstrates the suitability of the Cary 1E Spectrophotometer for following the photolysis in various media of fluphenazine & for measuring the change in UV-visible spectrum.- Application Notes
- English
- 25 Sep 2012
- 145.27 KB
- Brochures
- Flyers
- Posters
- Technical Overviews
- White Papers
Promotions
Related Products
Training & Events
靶向乳腺癌 BACH1 和線粒體代謝的有效聯合療法
在本次網絡研討會中,Jiyoung Lee 博士將介紹線粒體代謝作為癌癥治療靶標的相關研究。通過提高對線粒體的依賴性對代謝途徑進行重編程,可以提高代謝抑制劑的療效,從而抑制治療選擇有限的癌癥(如三陰性乳腺癌 (TNBC))。本研討會將介紹 BACH1(BTB-CNC 異體同源體 1)如何靶向 TNBC 細胞中的線粒體代謝。BACH1 是一種血紅素結合轉錄因子,在 TNBC 中呈高表達。使用 shRNA 或血紅素(氯化血紅素)阻斷 BACH1 可增強癌細胞對中心碳代謝的依賴,從而使其對線粒體抑制劑二甲雙胍敏感。血紅素和二甲雙胍的創新聯合可抑制乳腺腫瘤的生長。結果突出顯示了 BACH1 是線粒體代謝的關鍵調節因子,是 TNBC 對二甲雙胍響應的決定因素。
Webinar/Training
模擬人 T 細胞的抗腫瘤功能
小鼠型號相對 闡明 T 生殖神經元在抗腫癌對答中的功效至關比較重要,有時候因為成千上萬人類祖先祖先抵抗能力沒有與小鼠蛋白激酶的交叉的情況反應,由此它們的在流量轉化理論研究探討用得于得票數物理療法測試測試的效果有現。而是,絕大部分數使用理論研究探討抗腫癌 T 生殖神經元對答的依據人類祖先祖先生殖神經元的型號都會存在明顯的菌物學受限或具體受限,常見性有現。 在另行通知網絡上論壇會總結會中,基阿斯利康的 Michael Overstreet 醫生將講解體系結構抗病性毒的記憶 T 上皮體受損人體神經元核的仿真仿真模型系統的的創建,用作科學研究 HLA 相合人惡性肺部腫瘤上皮體受損人體神經元核的抗原特喜歡的人 T 上皮體受損人體神經元核介導的上皮體受損人體神經元核毒素運行。本論壇會總結會將提供如果運行時實器材調優該仿真仿真模型,才能對干擾惡性肺部腫瘤上皮體受損人體神經元核和 T 上皮體受損人體神經元核相互相互運行的動態圖片變量類型相互的影響發生新的明白。
Webinar/Training
定義人類受試者的生物能量代謝物相互作用組
在此次網絡研討會中,Victor Darley-Usmar 博士將介紹稱為生物能量-代謝物相互作用組的新概念,該概念描述了如何在單個細胞水平上定義生物能量代謝健康。盡管我們知道代謝狀況以及使用能量的方式反映了個體的反應,但是直到最近,要證明這種關系同樣適用于人類受試者仍然非常困難。這項研究有趣而令人驚訝的方面在于證明了我們所接觸的分子(暴露組)可以對新陳代謝產生直接且定量的影響,而且這種影響會因個體而不同。這些研究尚處于早期階段,但與此同時還出現了控制代謝的有趣的新方法,可作為控制與健康衰老相關疾病的預防策略。
Webinar/Training